Literature DB >> 9457513

Strontium plaque irradiation of subfoveal neovascular membranes in age-related macular degeneration.

A Jaakkola1, J Heikkonen, P Tommila, L Laatikainen, I Immonen.   

Abstract

PURPOSE: To determine the effect of focal strontium-90 plaque radiotherapy on subfoveal choroidal neovascularization in patients with age-related macular degeneration.
METHODS: Twenty patients with age-related macular degeneration, presenting with a recent subfoveal neovascular membrane, were treated with local episcleral radiotherapy using a strontium-90 applicator. The applicator was applied to the sclera under the macular region and held there tightly for 54 min to obtain a dose of 15 Gy at a depth of 1.75 mm. The main parameters evaluated at follow-up after 3, 6 and 12 months were visual acuity and changes in fluorescein angiography. Twelve untreated patients with the same criteria were followed as controls.
RESULTS: Early effects of radiation could be seen at 3 months, but became more obvious after follow-up for 6 and 12 months. At 6 months, regression of the choroidal neovascularization was detected in 14/19 patients (74%) as a decrease in the size of the lesion or as diminished leakage in late-phase fluorescein angiography. Likewise, in 14/19 patients (74%) at 12 months the neovascular membrane was partially or totally occluded. In all patients showing regression of the choroidal neovascular membrane, the neurosensory detachment had also dried. Visual acuity was unchanged (within 1 line) or improved in 11/20 (55%) and 9/20 (45%) treated patients after 6 and 12 months, respectively. In the controls, the choroidal neovascularization had increased in size in 9/12 patients (75%) at the last follow-up (mean 12.0 months). Visual acuity was unchanged in 3/12 patients (25%).
CONCLUSION: Local low-energy beta irradiation with a strontium-90 applicator can induce regression of choroidal neovascularization. The effect of irradiation is seen as a decrease in the size of the choroidal neovascular membrane and disappearance of the neurosensory detachment and exudates.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9457513     DOI: 10.1007/s004170050038

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  26 in total

1.  Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1990-06

2.  Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1991-09

3.  Theoretical calculations of dose distributions for beta-ray eye applicators.

Authors:  J Hokkanen; J Heikkonen; P Holmberg
Journal:  Med Phys       Date:  1997-02       Impact factor: 4.071

4.  Radiosensitivity of human endothelial cells in culture.

Authors:  R L De Gowin; L J Lewis; J C Hoak; A L Mueller; D P Gibson
Journal:  J Lab Clin Med       Date:  1974-07

5.  Treatment of age-related subfoveal neovascular membranes by teletherapy: a pilot study.

Authors:  U Chakravarthy; R F Houston; D B Archer
Journal:  Br J Ophthalmol       Date:  1993-05       Impact factor: 4.638

6.  Effects of irradiation on the eye.

Authors:  R C Chan; L J Shukovsky
Journal:  Radiology       Date:  1976-09       Impact factor: 11.105

7.  Focal irradiation of perforating eye injuries.

Authors:  U Chakravarthy; J H Biggart; T A Gardiner; D B Archer; C J Maguire
Journal:  Curr Eye Res       Date:  1989-12       Impact factor: 2.424

8.  [Low dosage radiotherapy of subfoveal neovascularization in age-related macular degeneration. Preliminary results].

Authors:  C Valmaggia; P Bischoff; G Ries
Journal:  Klin Monbl Augenheilkd       Date:  1995-05       Impact factor: 0.700

9.  Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1994-04

10.  Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration. The influence of initial lesion size and initial visual acuity. Macular Photocoagulation Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1994-04
View more
  7 in total

1.  [In Process Citation].

Authors: 
Journal:  Ophthalmologe       Date:  2015-11       Impact factor: 1.059

2.  Influence of eye size and beam entry angle on dose to non-targeted tissues of the eye during stereotactic x-ray radiosurgery of AMD.

Authors:  Justin L Cantley; Justin Hanlon; Erik Chell; Choonsik Lee; W Clay Smith; Wesley E Bolch
Journal:  Phys Med Biol       Date:  2013-09-12       Impact factor: 3.609

3.  Correlation between Octopus perimetry and fluorescein angiography after strontium-90 plaque brachytherapy for subfoveal exudative age related macular degeneration.

Authors:  A Jaakkola; E Vesti; I Immonen
Journal:  Br J Ophthalmol       Date:  1998-07       Impact factor: 4.638

Review 4.  Context for Protons as Adjunctive Therapy in Neovascular Age-Related Macular Degeneration: A Review.

Authors:  Stephanie R Rice; Matthew S J Katz; Minesh P Mehta
Journal:  Int J Part Ther       Date:  2016-03-24

5.  Long term results of radiotherapy for subfoveal choroidal neovascularisation in age related macular degeneration.

Authors:  M Mauget-Faÿsse; C Chiquet; D Milea; P Romestaing; J P Gérard; P Martin; F Koenig
Journal:  Br J Ophthalmol       Date:  1999-08       Impact factor: 4.638

6.  Palladium-103 plaque radiation therapy for macular degeneration: results of a 7 year study.

Authors:  P T Finger; Y P Gelman; A M Berson; A Szechter
Journal:  Br J Ophthalmol       Date:  2003-12       Impact factor: 4.638

7.  [The photon therapy of subfoveal choroidal neovascularization in age-dependent macular degeneration. The results of a prospective study in 40 patients].

Authors:  U Prettenhofer; A Haas; R Mayer; A Oechs; B Pakisch; H Stranzl; P Willfurth; A Hackl
Journal:  Strahlenther Onkol       Date:  1998-12       Impact factor: 3.621

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.